These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 18239973

  • 1. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
    de Bree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, Daskalakis M, Pilatou M, Sanidas E, Taflampas P, Kalbakis K, Beijnen JH, Tsiftsis DD.
    Ann Surg Oncol; 2008 Apr; 15(4):1183-92. PubMed ID: 18239973
    [Abstract] [Full Text] [Related]

  • 2. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer.
    Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Lee KH, Lee SH, Kim SJ.
    J Surg Oncol; 2010 Feb 01; 101(2):149-55. PubMed ID: 20035540
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
    Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A, Montruccoli D, Sammartino P.
    Cancer; 2008 Jul 15; 113(2):315-25. PubMed ID: 18473354
    [Abstract] [Full Text] [Related]

  • 5. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
    Lim SJ, Cormier JN, Feig BW, Mansfield PF, Benjamin RS, Griffin JR, Chase JL, Pisters PW, Pollock RE, Hunt KK.
    Ann Surg Oncol; 2007 Aug 15; 14(8):2309-18. PubMed ID: 17541691
    [Abstract] [Full Text] [Related]

  • 6. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.
    de Bree E, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, Beijnen JH, Georgoulias V, Tsiftsis DD.
    Eur J Surg Oncol; 2006 Aug 15; 32(6):666-70. PubMed ID: 16618534
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.
    Ansaloni L, Coccolini F, Morosi L, Ballerini A, Ceresoli M, Grosso G, Bertoli P, Busci LM, Lotti M, Cambria F, Pisano M, Rossetti D, Frigerio L, D'Incalci M, Zucchetti M.
    Br J Cancer; 2015 Jan 20; 112(2):306-12. PubMed ID: 25461804
    [Abstract] [Full Text] [Related]

  • 9. Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study.
    Muñoz-Casares FC, Rufián S, Arjona-Sánchez Á, Rubio MJ, Díaz R, Casado Á, Naranjo Á, Díaz-Iglesias CJ, Ortega R, Muñoz-Villanueva MC, Muntané J, Aranda E.
    Cancer Chemother Pharmacol; 2011 Jul 20; 68(1):267-74. PubMed ID: 21499894
    [Abstract] [Full Text] [Related]

  • 10. Volume therapy and cardiocircular function during hyperthermic intraperitoneal chemotherapy.
    Raue W, Tsilimparis N, Bloch A, Menenakos C, Hartmann J.
    Eur Surg Res; 2009 Jul 20; 43(4):365-72. PubMed ID: 19844110
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center.
    Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL.
    Ann Surg Oncol; 2008 Mar 20; 15(3):754-63. PubMed ID: 18080166
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer.
    Cascales Campos PA, Gil Martínez J, Galindo Fernández PJ, Gil Gómez E, Martínez Frutos IM, Parrilla Paricio P.
    Eur J Surg Oncol; 2011 Jun 20; 37(6):543-8. PubMed ID: 21489742
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
    Roviello F, Pinto E, Corso G, Pedrazzani C, Caruso S, Filippeschi M, Petrioli R, Marsili S, Mazzei MA, Marrelli D.
    J Surg Oncol; 2010 Nov 01; 102(6):663-70. PubMed ID: 20721959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.